Central Vein

  • XW04 Central Vein
    • XW043 Percutaneous
      • XW0432 Ceftazidime-Avibactam Anti-infective
        • XW04321 Introduction of Ceftazidime-Avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
      • XW0433 Idarucizumab, Dabigatran Reversal Agent
        • XW04331 Introduction of Idarucizumab, Dabigatran Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 1
      • XW0434 Isavuconazole Anti-infective
        • XW04341 Introduction of Isavuconazole Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 1
      • XW0435 Blinatumomab Antineoplastic Immunotherapy
        • XW04351 Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1
      • XW0437 Coagulation Factor Xa, Inactivated
        • XW04372 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
      • XW0439 Defibrotide Sodium Anticoagulant
        • XW04392 Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2
      • XW043A Bezlotoxumab Monoclonal Antibody
        • XW043A3 Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 3
      • XW043B Cytarabine and Daunorubicin Liposome Antineoplastic
        • XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
      • XW043C Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy
        • XW043C3 Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3
      • XW043F Other New Technology Therapeutic Substance
        • XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
      • XW043G Plazomicin Anti-infective
        • XW043G4 Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
      • XW043H Synthetic Human Angiotensin II
        • XW043H4 Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
      • XW043K Fosfomycin Anti-infective
        • XW043K5 Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
      • XW043N Meropenem-vaborbactam Anti-infective
        • XW043N5 Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
      • XW043Q Tagraxofusp-erzs Antineoplastic
        • XW043Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
      • XW043S Iobenguane I-131 Antineoplastic
        • XW043S5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
      • XW043U Imipenem-cilastatin-relebactam Anti-infective
        • XW043U5 Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
      • XW043W Caplacizumab
        • XW043W5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5